pradigastat   Click here for help

GtoPdb Ligand ID: 7830

Synonyms: LCQ-908 | LCQ908
Compound class: Synthetic organic
Comment: Pradigastat is a potent and selective inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1).
The PubChem CID 53387035 shows the molecule with no stereochemistry.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 75.11
Molecular weight 455.18
XLogP 5.75
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CC1CCC(CC1)c1ccc(cc1)c1ccc(cn1)Nc1ccc(nc1)C(F)(F)F
Isomeric SMILES OC(=O)C[C@@H]1CC[C@H](CC1)c1ccc(cc1)c1ccc(cn1)Nc1ccc(nc1)C(F)(F)F
InChI InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)/t16-,17-
InChI Key GXALXAKNHIROPE-QAQDUYKDSA-N
No information available.
Summary of Clinical Use Click here for help
Pradigastat has been granted orphan designation by the EMA (in 2012) and US FDA, for the treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia). Pradigastat (under research code LCQ908) has completed a Phase 2 clinical trial for type 2 diabetes (NCT00901979). A Phase 2 trial for coronary artery disease associated with hypertriglyceridemia is recruiting patients (NCT01474434), as is a Phase 2I trial for familial chylomicronemia syndrome (NCT01589237) (as of Nov 2014).